ENTRADA THERAPEUTICS INC
NASDAQ: TRDA (Entrada Therapeutics, Inc.)
Kemas kini terakhir: 1 jam lalu6.80
0.38 (5.92%)
| Penutupan Terdahulu | 6.42 |
| Jumlah Dagangan | 291,808 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.33 |
| Harga / Jualan (P/S) | 60.63 |
| Harga / Buku (P/B) | 1.13 |
| Julat 52 Minggu |
| Margin Keuntungan | 14.39% |
| Margin Operasi (TTM) | -105.99% |
| EPS Cair (TTM) | 0.580 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -65.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.66% |
| Nisbah Semasa (MRQ) | 21.88 |
| Aliran Tunai Operasi (OCF TTM) | -54.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -65.48 M |
| Pulangan Atas Aset (ROA TTM) | 0.51% |
| Pulangan Atas Ekuiti (ROE TTM) | 7.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Entrada Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.88 |
|
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.36% |
| % Dimiliki oleh Institusi | 80.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mpm Asset Management Llc | 30 Sep 2025 | 4,381,062 |
| 5Am Venture Management, Llc | 30 Jun 2026 | 4,056,379 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DOSHI DIPAL | - | 7.30 | -8,724 | -63,685 |
| DOWDEN NATHAN J | - | 7.30 | -2,528 | -18,454 |
| MPM BIOVENTURES 2014, L.P. | - | 7.15 | -130,741 | -932,460 |
| MPM BIOVENTURES 2018, L.P. | - | 7.15 | -130,741 | -932,460 |
| SETHURAMAN NATARAJAN | - | 7.30 | -2,079 | -15,177 |
| WENTWORTH KORY JAMES | - | 7.30 | -1,733 | -12,651 |
| Jumlah Keseluruhan Kuantiti Bersih | -276,546 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,974,887 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 7.20 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2014, L.P. | 03 Sep 2026 | Jual (-) | 32,263 | 7.17 | 231,326 | |
| MPM BIOVENTURES 2018, L.P. | 03 Sep 2026 | Jual (-) | 32,263 | 7.17 | 231,326 | |
| WENTWORTH KORY JAMES | Pegawai | 02 Sep 2026 | Dibuang (-) | 1,733 | 7.30 | 12,651 |
| SETHURAMAN NATARAJAN | Pegawai | 02 Sep 2026 | Dibuang (-) | 2,079 | 7.30 | 15,177 |
| DOWDEN NATHAN J | Pegawai | 02 Sep 2026 | Dibuang (-) | 2,528 | 7.30 | 18,454 |
| DOSHI DIPAL | Pegawai | 02 Sep 2026 | Dibuang (-) | 8,724 | 7.30 | 63,685 |
| MPM BIOVENTURES 2014, L.P. | 02 Sep 2026 | Jual (-) | 25,131 | 7.30 | 183,456 | |
| MPM BIOVENTURES 2018, L.P. | 02 Sep 2026 | Jual (-) | 25,131 | 7.30 | 183,456 | |
| MPM BIOVENTURES 2014, L.P. | 01 Sep 2026 | Jual (-) | 29,088 | 7.07 | 205,652 | |
| MPM BIOVENTURES 2018, L.P. | 01 Sep 2026 | Jual (-) | 29,088 | 7.07 | 205,652 | |
| MPM BIOVENTURES 2014, L.P. | 31 Aug 2026 | Jual (-) | 44,259 | 7.05 | 312,026 | |
| MPM BIOVENTURES 2018, L.P. | 31 Aug 2026 | Jual (-) | 44,259 | 7.05 | 312,026 | |
| Papar semua | ||||||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |